In recent years, several tumor biomarkers have been identified that help to classify breast cancer into subgroups that have different prognoses and treatment: the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) [9]. This evidence concerns the gene ERBB2 and neoplasm.